<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>quinoline derivatives &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/quinoline-derivatives/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 16 Oct 2026 06:09:14 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>quinoline derivatives &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Computational Screening Points to Two Quinoline Candidates Against Tuberculosis and Resistant Infections</title>
		<link>https://bioengineer.org/computational-screening-points-to-two-quinoline-candidates-against-tuberculosis-and-resistant-infections/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 16 Oct 2026 06:09:14 +0000</pubDate>
				<category><![CDATA[Chemistry]]></category>
		<category><![CDATA[ADMET prediction]]></category>
		<category><![CDATA[Antimicrobial Resistance]]></category>
		<category><![CDATA[DFT calculations]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[hERG cardiotoxicity]]></category>
		<category><![CDATA[KDR receptor]]></category>
		<category><![CDATA[Medicinal Chemistry]]></category>
		<category><![CDATA[molecular orbital analysis]]></category>
		<category><![CDATA[Oral bioavailability]]></category>
		<category><![CDATA[quinoline derivatives]]></category>
		<category><![CDATA[Tuberculosis]]></category>
		<category><![CDATA[virtual screening]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=421921</guid>

					<description><![CDATA[Computational screening of four halogenated quinoline derivatives identifies QNL1 and QNL3 as promising oral drug candidates against tuberculosis, E. coli, and aspergillosis, with QNL3 prioritized for its superior cardiovascular safety profile.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">421921</post-id>	</item>
	</channel>
</rss>
